These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 32622736)

  • 81. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
    Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
    Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
    El Rassy E; Bakouny Z; Assi T; Kattan J
    Future Oncol; 2018 Apr; 14(9):891-895. PubMed ID: 29527939
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study.
    Al-Rashdan A; Quirk S; Roumeliotis M; Abedin T; Amaro CP; Barbera L; Lupichuk S; Cao JQ
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):399-408. PubMed ID: 35870712
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels.
    Nakatsukasa H; Takahashi M; Takahashi K; Takashima T; Asano Y; Morisaki T; Kashiwagi S; Noda S; Nakamura Y
    Biol Pharm Bull; 2022; 45(10):1476-1481. PubMed ID: 36184505
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.
    Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):85-91. PubMed ID: 30577708
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
    Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
    Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
    Yap YS; Chiu J; Ito Y; Ishikawa T; Aruga T; Kim SJ; Toyama T; Saeki T; Saito M; Gounaris I; Su F; Ji Y; Han Y; Gazdoiu M; Masuda N
    Cancer Sci; 2020 Sep; 111(9):3313-3326. PubMed ID: 32619077
    [TBL] [Abstract][Full Text] [Related]  

  • 89. CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities.
    Lynce F; Shajahan-Haq AN; Swain SM
    Pharmacol Ther; 2018 Nov; 191():65-73. PubMed ID: 29933034
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor.
    Gebbia V; Valerio MR; Firenze A; Vigneri P
    Expert Opin Drug Saf; 2020 Aug; 19(8):945-954. PubMed ID: 32552035
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Severe acute radiation dermatitis after palbociclib therapy in the setting of palliative radiotherapy.
    Kim KN; Salerno M; Shah PD; Matro J; LaRiviere MJ
    J Oncol Pharm Pract; 2023 Apr; 29(3):764-767. PubMed ID: 35929120
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
    Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
    Agarwal N; Castellano D; Alonso-Gordoa T; Arranz Arija JA; Colomba E; Gravis G; Mourey L; Oudard S; Fléchon A; González M; Rey PM; Schweizer MT; Gallardo E; Johnston E; Balar A; Haddad N; Appiah AK; Nacerddine K; Piulats JM
    Clin Cancer Res; 2024 Jun; 30(11):2377-2383. PubMed ID: 38512117
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER
    Petroni G; Buqué A; Yamazaki T; Bloy N; Liberto MD; Chen-Kiang S; Formenti SC; Galluzzi L
    Clin Cancer Res; 2021 Apr; 27(7):1855-1863. PubMed ID: 33495311
    [TBL] [Abstract][Full Text] [Related]  

  • 96. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
    DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
    Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
    [TBL] [Abstract][Full Text] [Related]  

  • 97. CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity.
    Meynard L; Grellety T
    Breast J; 2020 Feb; 26(2):255-257. PubMed ID: 31495008
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer.
    Beddok A; Mouren V; Cottu P; Laki F; Fourquet A; Kirova Y
    Int J Cancer; 2023 Oct; 153(7):1386-1396. PubMed ID: 37381597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.